This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system and/or traditional antibiotics.

The invention relates to the field of medical diagnosis, particularly to methods and antibodies useful for the identification of colibactin producing bacteria (pks+ bacteria). Herein are disclosed peptides and antibodies that allow for the detection and isolation of pks+ bacteria, as well as uses and methods of use of said peptides and antibodies.

The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.

Polypeptides comprising a FimH lectin domain comprising an amino acid mutation that causes the FimH lectin domain to be in the low affinity conformation for mannose are described. Pharmaceutical compositions which comprise such polypeptides and methods of stimulating an immune response in a subject in need thereof by administration of the polypeptide are further described.

The present invention pertains to a vaccine comprising (a) an immunologically effective amount of a Streptococcus suis IgM protease antigen, (b) an immunologically effective amount of an Escherichia coli fibmrial antigen, and (c) an immunologically effective amount of a Clostridium toxoid, and also pertains to use of the vaccine in a method for protecting pigs against a pathogenic infection with Streptococcus suis, Escherichia coli and Clostridium.

Embodiments of the present invention provide methods for the treatment or prevention of infection-related immune conditions using compositions comprising IgM.

The present invention provides a method of producing a serum containing protective antibodies with mucosal immunity, a PAMI serum, against mucosa-related infectious pathogens from an adult pig or cattle comprising a step of administering the mucosa-related infectious pathogens to the adult pig or cattle via a mucosal route such as oral or nasal administration; and a method of preventing and/or treating mucosal infectious diseases in piglets and calves by orally or intravenously administering the PAMI serum produced by the method above to piglets or calves. In experiments conducted by the method of the present invention, piglets and young calves were successfully prevented and/or treated from infection with mucosa-related infectious pathogens.

The present disclosure relates to broadly neutralizing antibodies and uses thereof for treating a pathogen infection or a co-infection of multiple pathogens.

This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system and/or traditional antibiotics.

In one aspect, a formulation comprising (a) an antibody that specifically binds an enterotoxigenic Escherichia coli (ETEC) or a molecule produced by an ETEC and (b) an antibody that specifically binds a norovirus (NV) or epitope thereof, is provided. In another aspect, a method of treating or preventing Travelers' diarrhea using the formulation is provided.